Know Labs revealed the next stage in the development of its proprietary Bio-RFID™? technology - the Generation (Gen) 1 Device. Gen 1 incorporates Know Labs' Bio-RFID sensor - which has been proven as technically feasible and stable in delivering repeatable results in measuring blood glucose when used in a lab environment - in a portable device.

Currently, there are no medical-grade, commercially available, non-invasive means of measuring blood glucose. The completion of Gen 1 brings Know Labs closer to achieving its ultimate goal of delivering the world's first FDA-cleared non-invasive blood glucose monitor for the billions of people living with diabetes and pre-diabetes worldwide. The Gen 1 prototype is a portable research lab, designed to be a powerful data collection device.

Data collection in clinical research is the foundation for further algorithm development and refinement. This device will allow Know Labs to scale data collection tenfold, including testing across more diverse participant populations and scenarios. Further clinical research with the new Gen 1 Device is expected to generate tens of billions of data observations to process, which enables Know Labs to continue refining and optimizing algorithms to manage and interpret these large and novel datasets.

For 2023, Know Labs remains focused on external validation of its technology and contributing to its growing body of peer-reviewed evidence, which can be found at the company. The company will make further refinements to the Gen 1 Device as it works toward realizing its vision for the KnowU and UBand and bringing an FDA-cleared product to the marketplace.